Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03754608 · ClinicalTrials.gov registry record
Validating Imaging Biomarkers of Small Vessel Disease in Diabetic Individuals Using Advanced MRI Techniques.
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 63
- Enrollment target
NCT03754608: Completed study, sponsored by Yale University.
NCT03754608 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03754608 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
Study Summary
To develop a set of biomarkers for imaging of small vessel disease in diabetic individuals using advanced MRI techniques. With this the investigators want to document progression of disease both radiologically and clinically.
Primary Outcome
This will be calculated from the sensitivity and specificity as compared to clinical diagnosis.
Interventions
- DIAGNOSTIC_TEST MRI including cf-MRI, DTI, ASL and CVR.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-11-07 |
| Est. Completion | 2020-08-31 |
What the finished NCT03754608 record still lists
NCT03754608 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which MRI including cf-MRI, DTI, ASL and CVR. is the first listed.
NCT03754608 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03754608 about?
NCT03754608 is a clinical study titled "Validating Imaging Biomarkers of Small Vessel Disease in Diabetic Individuals Using Advanced MRI Techniques.". To develop a set of biomarkers for imaging of small vessel disease in diabetic individuals using advanced MRI techniques. With this the investigators want to document progression of disease both radiologically and clinically.
What is the current status of trial NCT03754608?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2018-11-07. Estimated completion is 2020-08-31.
What interventions are being tested in trial NCT03754608?
The interventions under investigation include: MRI including cf-MRI, DTI, ASL and CVR. (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03754608?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI